Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cav1.3 is an L-type voltage-gated calcium channel encoded by the CACNA1D gene. It plays a critical role in various physiological processes, including pacemaking activity in the heart, neurotransmitter release, and hormone secretion. It's characterized by a more negative activation threshold compared to other L-type channels and is a target for dihydropyridines and other calcium channel blockers. Mutations and dysregulation are linked to cardiac arrhythmias, neuropsychiatric disorders, and hearing loss. Emerging evidence suggests its involvement in certain cancers, making it a potential therapeutic target.
Blocks calcium influx through the channel pore, reducing intracellular calcium levels.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-type Calcium Channel alpha(α)₁D Subunit.